[
  {
    "ts": null,
    "headline": "Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval",
    "summary": "Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a must-watch. Read more on IONS stock here.",
    "url": "https://finnhub.io/api/news?id=c147bb3682f8801342414e0c14009394d6ffbd5f6cd03234c4043a82013f96c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739976042,
      "headline": "Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval",
      "id": 132790634,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1914834329/image_1914834329.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Ionis Pharmaceuticals beats Q4 earnings, eyes sHTG market with TRYNGOLZA. Strong pipeline and cash position make it a must-watch. Read more on IONS stock here.",
      "url": "https://finnhub.io/api/news?id=c147bb3682f8801342414e0c14009394d6ffbd5f6cd03234c4043a82013f96c7"
    }
  },
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment",
    "summary": "Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.",
    "url": "https://finnhub.io/api/news?id=a53e3f2d4cb44040ef8a777ee8be9ce76cb2a5ba6837a11bf2837e748d8f53f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739966153,
      "headline": "Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment",
      "id": 133191260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Stoke will obtain a $165m upfront payment from Biogen upon completion of the transaction.",
      "url": "https://finnhub.io/api/news?id=a53e3f2d4cb44040ef8a777ee8be9ce76cb2a5ba6837a11bf2837e748d8f53f7"
    }
  },
  {
    "ts": null,
    "headline": "We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative",
    "summary": "Biogen Inc.'s ( NASDAQ:BIIB ) recent earnings report didn't offer any surprises, with the shares unchanged over the...",
    "url": "https://finnhub.io/api/news?id=615a7597099aa74cccc44564c96f628f0ff0b81905f90ff640bd7872a54dc74d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739963545,
      "headline": "We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative",
      "id": 133191261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc.'s ( NASDAQ:BIIB ) recent earnings report didn't offer any surprises, with the shares unchanged over the...",
      "url": "https://finnhub.io/api/news?id=615a7597099aa74cccc44564c96f628f0ff0b81905f90ff640bd7872a54dc74d"
    }
  }
]